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The Importance of Individualized Pharmaceutical
Therapy in the Treatment of Diabetes Mellitus
DAVID B. NASH, M.D., M.B.A., JENNIFER B. KOENIG, M.S., KAREN D. NOVIELLI, M.D.,
RENEE LIBERONI, M.P.H., and MIRIAM REISMAN, M.F.A.

ABSTRACT
Individualized pharmaceutical care for patients with diabetes is necessary for several reasons.
First, diabetes is a highly complex disease caused by the interplay among genetic, physiological, and environmental factors that vary from individual to individual. Second, the profile of patients with diabetes has evolved to include people of all ages and socioeconomic
backgrounds, with varying medical histories and health behaviors. Third, diabetes often occurs concurrently with other medical conditions, especially in certain groups, such as the elderly. While the treatment goals for all patients with diabetes are the same—to stabilize and
maintain healthy blood glucose levels to prevent serious complications—the treatment plan
used to achieve those goals will vary among individuals. There are many clinically proven
options available for the treatment of diabetes. While there are well-established guidelines
regarding which intervention is the best option for patients with either type 1 or type 2 diabetes, individual patient characteristics and needs should drive the care process. Assuring patient access to the wide variety of medications is crucial to meeting these needs and achieving quality, cost-effective diabetes management.

EXECUTIVE SUMMARY

D

is a complex disease with
a prevalence that is rapidly growing, especially among certain groups of Americans.
In the United States nearly 6% of the total population (approximately 16 million people) has
diabetes.1 Hispanics, African Americans, the
elderly, children, and the clinically obese are at
high risk for the disease.1–5 The impact of diabetes is felt economically, clinically, and socially. This chronic condition drains limited
healthcare dollars, tests the boundaries of clinical resources, and decreases quality of life for
patients and their families.
The insidious nature of diabetes compounds
IABETES MELLITUS

the threats it poses; up to one third of people
with diabetes in America are undiagnosed,1 despite the fact that diabetes can be identified
through a simple blood test.3 But patients are
often asymptomatic in the early stages, going
untreated until their bodies have sustained irreversible damage. These effects take a high toll
on individual patients and on America’s
healthcare system overall. Diabetes is the sixth
leading cause of death from disease, and its
combined direct and indirect costs total nearly
$100 billion annually.2
Controlling diabetes is a clinical challenge for
several reasons. First, diabetes is a highly complex illness caused by the interplay among genetic, physiologic, and environmental factors
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that vary from individual to individual.6 Careful monitoring and intensive therapy are required to avoid serious complications. As environmental and physiologic factors fluctuate,
drug therapy that was once effective may require modification.
Second, the diabetic population is changing.
At one time, diabetes was primarily considered
a disease of people with atypical genes (type 1)
or long lifespans (type 2). Now, epidemiologists know that diabetes affects a larger, more
diverse group of people. While socioeconomic
and technological changes have caused Americans to live longer (thanks to modern medicine), they have also encouraged unhealthy
lifestyles (thanks to modern conveniences),
putting more people at greater risk for developing diabetes today.7–8 In addition, there is
greater diversity among individuals who develop diabetes. For example, in the past, diabetes in children was almost always type 1; recently, increases in childhood type 2 diabetes
have been reported. 1 Although similar in age,
a child with type 1 diabetes would need a different treatment plan than a child with type 2
diabetes. Greater patient diversity warrants
greater therapeutic diversity.9
Third, diabetes often occurs along with other
medical conditions, especially in the elderly.11–14 Diseases that frequently coexist with
diabetes include cardiovascular disease, depression, obesity, and arthritis. Diabetes with
comorbid conditions presents a greater treatment challenge due to potential disease synergies, drug interactions, and compromised
physiologic reserves.9
The profile of patients with diabetes has
evolved to include people of all ages and socioeconomic backgrounds, with varying medical histories and health behaviors. As the patient population diversifies, management of
diabetes must address the differences among individual patients.9 While the treatment goals for
all people with diabetes are the same—to stabilize and maintain healthy blood glucose levels
to prevent serious complications—the treatment
plan used to achieve those goals will vary. Imagine three patients: an 8-year-old male with type
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1 diabetes but no other health problems, a 48year-old female with mild type 2 diabetes and
coexisting heart disease, and a 72-year-old male
with advanced type 2 diabetes and significant
diabetes-related sequelae. The clinical differences alone call for somewhat different treatment plans. When socioeconomic variables are
added to the mix (e.g., diet, exercise, living environment, availability of medications, involvement of caregivers), markedly different management strategies may be required.
Fortunately, the past few decades have seen
the development of a myriad of treatment options to address the specific needs of individuals with diabetes. Breakthrough innovations include the synthesis of human insulin in the
1980s and effective insulin analogues with improved properties in the 1990s. Incremental innovations in pharmacotherapy have been
equally valuable in children and elderly patients with diabetes.9 For instance, alternative
dosage forms encourage patient adherence by
meeting patient-specific needs,15 and newer insulin analogues offer improved side effect profiles.16 Recombinant DNA technology has
made some of these innovations possible, and
biomedical technologies will continue to play
an important role in future research and development. 17–19 Treatments for type 2 diabetes
have also been expanded to include more than
20 different medications that reduce blood glucose levels in several different ways. The variety of medications helps patients who are
prone to side effects or have difficulty adhering to their regimens to find a management
plan that is effective for them. Newer oral diabetes medications have reduced the potential
for hypoglycemic reactions, and increased options encourage adherence to treatment plans.
Yet despite the improvements in diabetes
treatment and education, the prevalence of the
terrible consequences of diabetes continues to
increase at an alarming rate. Therefore, still
greater efforts are necessary. To this end, we
offer this paper as a diabetes management approach that may help thwart the disease and
its high human and economic costs. This approach focuses on the benefits of individual-
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ized diabetes care. With the many pharmaceutical options available today, treatment can be
tailored to specific patients and groups. But the
availability of these medications is not enough.
High-quality, cost-effective diabetes care can
be achieved only if: (1) the patient’s specific
needs are accurately identified, and (2) there is
access to the wide variety of diabetes drugs to
match these needs. To foster a successful match
between each patient and his or her drug therapy, many factors—clinical, social, and economic—must be considered. The final section
of the paper provides a simple tool that encourages patients, providers, and policy-makers to bear in mind the key aspects of individualized care in the fight against diabetes.
INTRODUCTION: DIABETES BASICS
Epidemiology of diabetes
In the United States nearly 6% of the total population (or 15.7 million people) has diabetes. Diabetes contributes to more than 193,000 deaths
per year, and its annual incidence has increased
sixfold since 1958.1 Diabetes has become more
prevalent over the last two decades. The incidence of diabetes began rising in the early 1980s,
leveled off in the middle of the decade, and then
increased sharply in the 1990s. Between 1980
and 1996, the number of persons with diagnosed
diabetes in the United States increased from 5.8
million to 8.5 million.20 By 1997, the number of
persons with diagnosed diabetes had risen to
10.3 million, with 798,000 new cases diagnosed
per year; an additional 5.4 million are believed
to have undiagnosed diabetes. Diabetes is a
growing problem among the elderly, children
and adolescents, and the clinically obese. Certain ethnic groups, such as Native Americans,
Latinos, and African Americans, are also at
greater risk for the disease (Table 1).2,3
The number of persons with diagnosed diabetes, particularly type 2 diabetes, is increasing
for several reasons: (1) improvements in
screening and change in the diagnostic criteria
from a fasting plasma glucose greater than or
equal to 140 to one that is greater than or equal

TABLE 1. PREVALENCE OF DIABETES IN
DIFFERENT ETHNIC GROUPS COMPARED TO
OVERALL U.S. POPULATION
Subgroup
Puerto Ricans
Mexican Americans
Cuban Americans
Native Americans
African Americans
Overall U.S. population

Percentage of persons
with diabetes
26
24
16
12
11
6

to 126; (2) increasing rates of obesity and sedentary lifestyles; (3) growth in populations that
have high rates of type 2 diabetes21; (4) recognition that type 2 diabetes is an increasing
problem in children and adolescents22; and (5)
an aging population.
Definition of types 1 and 2
Diabetes mellitus is a group of diseases in
which hyperglycemia (elevated blood glucose)
results from inadequate production or use of insulin, the hormone secreted by the pancreas that
lowers blood sugar. Insulin is an essential element for many bodily functions: it allows glucose (sugar) to enter body cells where it is used
as energy, and it helps the body synthesize protein and store fat. When insulin availability or
function is compromised, glucose and lipids remain in the bloodstream instead of being converted to energy. Over time, excess glucose and
lipids damage the body’s organs, having particularly deleterious effects on the heart.1
Diabetes occurs in two forms: type 1, previously called insulin–dependent diabetes mellitus, and type 2, previously called non-insulin–dependent diabetes mellitus. Table 2
compares the features of the two major types
of diabetes. In type 1 diabetes, the body completely lacks insulin. This type of diabetes generally appears in patients before the age of 18
and accounts for about 5%–10% of all cases of
diabetes mellitus. It is caused by an autoimmune process that destroys the insulin-producing cells of the pancreas. Although a diabetes-specific diet, moderate exercise, and
other healthy habits can help patients reduce
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TABLE 2.

COMPARISON

OF

TYPE 1

AND

TYPE 2 DIABETES

Type 1 diabetes

Type 2 diabetes

Prevalence

5–10% of cases

90–95% of cases

Age of onset

Usually before 18

Usually after 45

Cause

Body’s inability to produce
insulin

Body’s inability to produce
enough insulin or resistance to
insulin

Common symptoms

Frequent urination or need to
urinate; excessive thirst;
extreme hunger; fatigue;
unusual weight loss; irritability

Same as type 1 symptoms
and blurred vision; tingling in
hands or feet; increased
susceptibility to infection; slow
to heal cuts and bruises;
recurring skin, gum or bladder
infections

Number with disease who
develop symptoms

100%

33%

Risk factors

Exposure to environmental
triggers (i.e., unidentified
virus); having sibling or parent
with type 1 diabetes

Obesity; advancing age (451);
family history; ethnicity;
malnutrition; inactivity; high
cholesterol levels; history of
gestational diabetes; having a
baby weighing 9 lbs. or more at
birth

Treatment

Diet control; exercise; home
blood glucose testing; and
daily insulin injections

Diet control; exercise; home
blood glucose testing; and, in
some cases, oral medication
and/or insulin

their glucose levels and avoid complications,
type 1 diabetes always requires insulin therapy
to counterbalance the absence of naturally occurring insulin.23
Type 2 diabetes is the most common form of
diabetes, representing 90%–95% of all cases diagnosed. In type 2 diabetes, the body is either
deficient in its insulin production, or resistant to
insulin, or both. Insulin resistance occurs when
the body’s cells no longer respond properly to
insulin and their ability to take up glucose is impaired, although insulin is available. Most type
2 diabetes develops in adulthood, although recent increases in children represent an alarming
trend. Their increases appear to correspond with
increases in obesity and inactivity among this age
group. Generally, patients with type 2 diabetes
are obese.23 Other rare, nonchronic forms of diabetes account for 1%–2% of all diagnosed cases.
Symptomatology
Although all people with type 1 diabetes develop symptoms, only approximately one third

of type 2 sufferers do, perhaps accounting for
the large number of undiagnosed cases. Symptoms common to both types of diabetes include
frequent urination or need to urinate, excessive
thirst, extreme hunger, fatigue, unusual weight
loss, and irritability.24
Risk factors and diagnostics
Although diabetes goes undetected in many
people, a lack of diagnostic tests is not the problem. Diagnosing diabetes is as simple as determining a plasma glucose level using a simple
blood test. Two consecutive days of either a
fasting glucose level of 126 mg/dL or greater
or a nonfasting glucose level of 200 mg/dL or
greater with symptoms indicates diabetes.3
The real problem with diagnosing diabetes is
getting people at risk tested for the disease.
Many people are not aware that they are at risk
or already have diabetes. Risk factors for type
2 diabetes include obesity, advanced age (45
years and over), family history, ethnicity, malnutrition, inactivity, dyslipidemia (high choles-
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terol levels), and history of gestational diabetes
or bearing a child weighing more than nine
pounds at birth.23 Anyone with one or more of
these risk factors should be tested for diabetes.
Consequences of untreated or inadequately
treated diabetes
Untreated type 1 diabetes has serious repercussions, specifically ketoacidosis. Ketoacidosis, also known as diabetic coma, is a metabolic
crisis that occurs when poorly controlled diabetes causes high blood glucose levels. If no
medical intervention occurs, ketoacidosis can
lead to coma and death. When type 2 diabetes
goes undetected and untreated, complications
develop more slowly than in type 1 diabetes
but can be just as serious. 23,24 These complications may include one or more of the following conditions: eye disease and blindness,
nerve damage, kidney failure, foot and leg ulcers that can lead to amputation, heart disease,
stroke, and narrowing of the arteries. These
complications also may occur in patients with
type 1 disease.
Untreated or inadequately treated diabetes
and its resultant complications cause substantial clinical and economic burdens of nearly
$100 billion annually. Substantial costs are incurred not only for diabetes-related direct medical expenditures, but also for the indirect costs
of disability and lost productivity resulting
from diabetes-related morbidity and premature mortality.25 According to the American Diabetes Association, the total estimated annual
economic cost of diabetes in the United States
in 1997 was $98 billion dollars. This figure includes $44 billion in direct medical and treatment costs and $54 billion for indirect costs attributed to disability and mortality. In 1997, the
per capita costs of healthcare for people with
diabetes amounted to $10,071, compared with
$2,699 for people without diabetes.25
Diabetes management
Studies have proven that diabetic complications can be minimized or avoided by maintaining normal or near-normal blood glucose
levels. The Diabetes Control and Complica-
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tions Trial (DCCT), a landmark 10-year clinical
study, established that intensive treatment of
diabetes delays the onset and slows the progression of diabetes complications.27 The
DCCT confirmed that maintaining a healthy
blood glucose level at an average of 155 mg/dL
reduces the long-term risk of nerve and eye
damage and kidney disease.27 The patients
studied in the DCCT were under 40 years old
and were diagnosed with type 1 diabetes; however, analogous findings have been documented in older patient populations with either
type 1 or type 2 diabetes.
Early intervention may be the key to limiting the severity of diabetes complications.28
The United Kingdom Prospective Diabetes
Study (UKPDS), the most comprehensive study
of patients with type 2 diabetes to date, followed 5,102 persons newly diagnosed with
type 2 diabetes for an average of 10 years. This
study confirmed and extended previous evidence in support of the hypotheses that hyperglycemia is a major cause of the microvascular complications of diabetes, and that
cardiovascular outcomes are consistently associated with hyperglycemia irrespective of its
underlying cause.29
Based on the DCCT and other important diabetes studies, the American Diabetes Association states that strict blood glucose control can
have similar benefits in all types of diabetes because the complications of uncontrolled hyperglycemia develop through similar pathologies, regardless of how the underlying disease
occurs. In other words, while type 1 and type
2 diabetes may not always be treated using the
same therapies, the end result of any effective
therapy—a consistently healthy blood glucose
level—will prevent or delay complications in
either condition. Details about diabetes treatment options are described in the subsequent
section.

PHARMACOLOGIC MANAGEMENT
OPTIONS FOR DIABETES
There are many clinically proven pharmacologic and nonpharmacologic interventions to
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control blood glucose levels for people with diabetes. Nonpharmacologic interventions include diet, exercise, and other behavioral modifications. Proper nutrition and exercise are a
fundamental part of treating both type 1 and
type 2 diabetes.
Pharmacologic treatment guidelines differ
for type 1 and type 2 diabetes. Because people
with type 1 diabetes cannot produce any insulin, they must inject it daily. Insulin reduces
glucose levels by suppressing glucose production in the liver and by increasing glucose utilization after meals.30 A patient with type 2 diabetes may require oral drug therapy alone or
in combination with insulin therapy.
Well-established clinical practice recommendations generally guide the decision regarding
which intervention is the best option for diabetes patients.26 But individual patient characteristics should drive the care process, suggesting where interventions should begin, and in
which direction care will proceed. Because diabetes is a progressive, incurable illness, the
pathways are multidirectional and dynamic;
that is, interventions almost always need modification over a patient’s lifetime.
Nonpharmacologic management: the first line of
defense against diabetes
The first interventions in diabetes management are nonpharmacologic. Even for patients
with type 1 diabetes, for whom insulin therapy is always required, it is also important to
use nonpharmacologic strategies to control
blood glucose levels and to improve general
health. For patients with type 2 diabetes, nonpharmacologic interventions may be enough
to control diabetes, at least initially. Nonpharmacologic interventions control blood glucose
levels by balancing insulin production and
sensitivity with nutrition and exercise. Firstline therapy for type 2 diabetes calls for an adjustment in diet and exercise; for overweight
patients, often a short trial of weight reduction
and exercise is recommended before the initiation of pharmacotherapy.26 Exercise can facilitate weight loss, and it helps to improve insulin sensitivity, allowing the body to use
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insulin more efficiently. In addition to lowering blood glucose levels, diet and exercise can
help improve a patient’s lipid profile (i.e., reduce
cholesterol levels), which is important for avoiding the cardiovascular complications of diabetes. Other behavior modifications, such as
avoiding alcohol and tobacco, can also help
manage diabetes and its complications.

Oral drug therapy
If and when nonpharmacologic treatment no
longer controls blood glucose levels adequately, oral antidiabetic medications are generally the next step for people with type 2 diabetes. These medications may be used alone, in
combination with one another, or as an adjunct
to insulin. Oral medications for diabetes reduce
blood glucose levels in several different ways.
Some increase the amount of insulin secreted
from the pancreatic beta cells. Others allow the
body to use the insulin that is already present
more effectively. A third group reduces the
breakdown of carbohydrates in the gastrointestinal tract so that less sugar is absorbed.
Some medications use a combination of these
methods to manage blood glucose levels.
No single currently available agent appears
to be superior when used as monotherapy, and
combination therapy is often indicated. Many
people with diabetes need to use more than one
kind of medication to manage both their insulin
production and insulin resistance. If a patient
does not respond to a first-line agent, a second
agent is typically added, not substituted.31
It is important to note that people with type
2 diabetes are not the only patients who may
benefit from noninsulin oral medications. Although oral antidiabetic agents cannot be used
as primary therapy for persons suffering from
type 1 diabetes, these individuals may also benefit from therapy with a combination of oral
drugs and insulin. For example, a-glucosidase
inhibitors used in addition to an insulin regimen have decreased the early peak in blood
glucose following meals, thus minimizing the
subsequent drop in plasma glucose, evening
out glucose levels overall.32
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The remainder of this section describes the
major classes of noninsulin oral drug therapy
available for the treatment of diabetes.
Sulfonylureas. Sulfonylureas work in two ways:
they increase insulin production and reduce insulin resistance. They are taken one or more times
a day and require careful monitoring to avoid a
low blood sugar reaction (hypoglycemia). This
class includes the following drugs:





First Generation
Acetohexamide
Chlorpropamide
Tolazamide
Tolbutamide

Second Generation
 Glimepiride
 Glipizide
 Glyburide

The decision to use a sulfonylurea and the
choice among the available agents will depend
greatly on the individual characteristics of the
patient. Generally, second-generation sulfonylureas are preferable because they interact with
fewer drugs and have a more favorable side effect profile. They are long-acting, allowing for
once-daily dosing that may encourage adherence to drug regimens. Sulfonylureas with short
half-lives tend to minimize hypoglycemic
episodes; patients prone to such episodes will
usually benefit from shorter acting agents such
as glipizide and should avoid the long-acting
medications such as chlorpropamide. Patients
with compromised kidney or liver function
should be monitored especially closely when
taking sulfonylureas because these drugs are
processed renally and hepatically. This applies
to the elderly and patients with comorbid disease(s) that affect these organs.9 For these individuals, dosages should begin low (about half
the recommended starting dose) and be titrated
cautiously. Sulfonylureas are not indicated for
patients with severe kidney or liver disease.
Biguanide. An alternative or adjunct to sulfonylureas is metformin, the only currently
available biguanide. It controls blood glucose
levels by acting on the liver to ensure that it
does not produce excessive amounts of sugar.16
An additional benefit of metformin is that it
promotes weight loss and reduction in blood fat
and cholesterol levels, all of which can contrib-
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ute to better blood glucose control. However,
alcohol use or kidney disease may preclude the
use of this agent. Metformin (Bristol-Myers
Squibb Co., Princeton, NJ) can also encourage
anorexia, so it may not be preferable for older
patients for whom malnutrition is a concern. In
general, though, this agent is a good option for
the elderly because unlike sulfonylureas and insulin, metformin does not contribute to hypoglycemia.9 Metformin is generally taken two or
three times per day with meals.
a-Glucosidase inhibitors. a-Glucosidase inhibitors function by blocking gastrointestinal enzymes that digest carbohydrates, thus slowing
and reducing the production of sugar from
these foods. Two a-glucosidase inhibitors are
currently available: acarbose and miglitol. To
maximize effectiveness, these medications are
taken three times daily at mealtime. Like metformin, a-glucosidase inhibitors do not cause
hypoglycemia when taken alone. Acarbose also
has a stool-softening effect that may be desirable in patients prone to constipation.16
Thiazoldinediones. The thiazolidinediones include rosiglitazone and pioglitazone. The first
thiazolidinediones, troglitazone, was removed
from the U.S. market because of rare but severe
hepatotoxicity.16 Thiazolidinediones are indicated for type 2 diabetes; they sensitize the
body to its own insulin or to insulin therapy.
They can be used alone or with other medications such as metformin, sulfonylureas, or insulin; however, they have not been tested with
a-glucosidase inhibitors. Taken alone, thiazolidinediones do not cause hypoglycemia; with
insulin or insulin analogues hypoglycemia can
occur. The currently available thiazolidinediones can have a positive effect on the lipid
profiles, and they do not have adverse effects
on the liver or kidneys. Thiazolidinediones can
reduce the effectiveness of oral contraceptives.
New combined oral medications. In August 2000,
the Food and Drug Administration (FDA) approved the first fixed dose combination oral antidiabetic, Glucovance (Bristol-Myers Squibb
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Co., Princeton, NJ). Glucovance combines the
two most often prescribed oral diabetes medications—glyburide and metformin—in one
tablet. This new approach to the management
of type 2 diabetes is indicated as first-line therapy for newly diagnosed diabetes, and is also
indicated as second-line therapy for patients
who have been taking metformin or a sulfonylurea alone without clinical success.34
Insulin and insulin analogues. Insulin or insulin analogs are required for all people with
type 1 diabetes and some people with type 2
diabetes to maintain adequate blood glucose
control. Because of progressive decline in beta
cell function in type 2 diabetes, even the use of
multiple oral medications is sometimes not adequate, and eventually many people with type
2 diabetes will require insulin therapy either in
combination with the oral therapies or instead
of them.30 Currently 40% of people with type
2 diabetes use insulin. The need for insulin increases with duration of the disease.30
Today, there are more than 20 types of FDAapproved insulin available in the United States.35
Insulin therapies vary in how they are manufactured, how they function in the body, and how
they are administered. Because each person responds to insulin uniquely, these different treatment options allow therapy to be individualized
to meet the needs of specific patients.
Varieties of insulin by species type. Insulin can
be derived from several animal species. In the
past, insulin derived from cows and pigs was
used to treat diabetes. Synthetic human insulin,
developed using recombinant DNA technology,
is now used. Bovine (cow) and porcine (pig) insulins were extracted from the pancreas and
processed so the human body would accept it.9
However, allergic reactions occurred in some
individuals who used insulin from nonhuman
sources. Human insulin is not extracted from
humans but synthesized in laboratories and is
identical to the naturally occurring insulin.36
Varieties of insulin by duration of action. The
availability of many types of insulin with vary-
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ing durations of action provides options for patients with diverse needs. Insulin may be rapidacting, short-acting, intermediate-acting, or
long-acting. Rapid-acting insulin (Lispro, Eli
Lilly and Co., Indianapolis, IN) reaches the
blood within 15 minutes after injection. It peaks
30 to 90 minutes later and may last as long as
5 hours. Short-acting (regular) insulin usually
reaches the blood within 30 minutes after injection. It peaks 2 to 4 hours later and stays in
the blood for about 4 to 8 hours. Intermediateacting (NPH [neutral protamine Hagedorn]
and lente) insulins reach the blood 2 to 6 hours
after injection. They peak 4 to 14 hours later
and stay in the blood for about 14 to 20 hours.
Ultralente insulin is a long-acting insulin that
takes 6 to 14 hours to start working. It has no
peak or a very small peak 10 to 16 hours after
injection. It stays in the blood between 20 and
24 hours. Insulin glargine is a long-acting insulin with a relatively constant blood level over
24 hours without a peak.
Because it is common for people with diabetes
to use more than one type of insulin, some insulins are available as combination therapies.
For example, a combination of regular insulin
and NPH insulin is available as a premixed solution. This can be convenient because it reduces
the number of injections required to control
blood glucose. However, the ratio of insulins
cannot be adjusted as needed. For this reason,
some patients prefer to mix their own insulin.
Varieties of insulin by method of delivery. Most
often, insulin is self-injected subcutaneously 2
to 4 times per day. Traditionally, syringes are
used, but special delivery devices such as insulin pumps and pens are also available. Although these devices still use a needle, some
patients are more comfortable using them.
Insulin pens can be a convenient option. The
pen contains a premeasured amount of insulin,
but patients can use variable amounts depending on their particular needs at the time of dosing. The pen has a dial that is turned to select
the amount of insulin desired. After an insulin
pen has been opened, it can be stored at room
temperature and reused over a period of days.

PHARMACEUTICAL THERAPY FOR DIABETES MELLITUS
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However, patients should use a replacement
needle for each injection.16
Continuous subcutaneous insulin infusion using a pump is another option for insulin delivery. Insulin pumps, which were first developed
20 years ago, provide a continuous flow of insulin to the blood that more closely mimics the
way the body produces its own insulin compared to daily injections. The design and technology has evolved over the years to be more
accommodating to patients. The battery-operated device is continuously worn external to the
body, requiring a commitment by patients, their
families, and providers to ensure its consistent,
appropriate use. The use of the pump has risen
sharply in the past few years, particularly
among adolescents, suggesting its convenience
and efficacy for maintaining good blood glucose
levels without the need for injection twice to
four times daily.37 Compared to traditional intensive insulin therapy, the insulin pump has
achieved a 10% greater reduction in blood glucose levels when used by patients age 12 to 20.
According to results from the DCCT, this could
translate to a reduction in retinopathy (diabetic
eye disease) of up to 42%.38

everyone (e.g., patients with lung impairment
may not benefit from inhaled insulin), nor will
any one method completely remove the need for
injections for everyone (e.g., inhalers will probably be adjunctive therapy to long-acting and intermediate-acting injections). The availability of
alternative delivery devices and dosage forms
and routes of administration will allow for
greater individualization of care, perhaps encouraging greater adherence and tighter blood
glucose control, and thus improving clinical and
economic outcomes.
Despite many innovations, managing diabetes
consistently over time is still a challenge. No one
particular management strategy will work for
everyone with diabetes for several reasons: the
dual nature of the disease (type 1 vs. type 2), its
multifactorial etiology including genetic, physiologic and environmental factors, and the diversity of individual sufferers. Therefore, identifying an effective strategy for managing diabetes
is best accomplished on a case-by-case, patientby-patient basis.9 Table 3 compares diabetes
management strategies in terms of indications,
benefits, and major side effects.

Future delivery systems. Although pens and
pumps have allowed people with diabetes
some degree of choice and convenience, other
insulin delivery devices currently in development could expand future options. The primary objective of many of these devices is to
reduce or obviate the necessity of needles entirely. Inhalers containing insulin powders and
liquids are now being tested, as are transdermal
patch systems and oral sprays.15 Although these
methods require further testing to elucidate their
safety and efficacy, there is a real possibility of a
noninjectable insulin in the relatively near future.
Such innovations will give people with diabetes
greater latitude in their choice of treatment options, allowing them to match their treatment to
their own wants and needs. Inhalers and patches
may work well for people who travel often, who
cannot easily interrupt work or other activities
to inject, or who are simply uncomfortable with
needles. But each method may not work for

INDIVIDUALIZING CARE FOR
PATIENTS WITH DIABETES
Why is individualized pharmaceutical care needed?
Controlling diabetes demands individualized patient care for several mutually dependent reasons. First, the origin of disease in
diabetes is complicated, dynamic, and multifactorial. Second, the diabetic population is becoming more diverse in age, ethnicity, overall
health, and other characteristics. Third, diabetes often occurs concurrently with other
medical conditions, especially in certain groups
such as the elderly. These factors suggest that
pharmaceutical care should be tailored to meet
patient-specific characteristics and needs. Fortunately, there are many diabetes medications
available in different dosage forms and quantities with varying duration of action, mechanism of action, and side-effect profiles. Despite
the array of choices, there are still sufferers who
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Benefits

DIABETES MANAGEMENT STRATEGIES

Do not cause hypoglycemia when taken alone
Currently available agents have positive effect
on lipid profile and do not show adverse
effects on liver

Thiazolidinediones

FDA, Food and Drug Administration.

More than 20 types of FDA-approved allow for
individualized therapy
Available as combination products which
reduces number of injections required
New and improved methods of delivery

Help slow the digestion of some carbohydrates
Do not cause hypoglycemia when taken alone
Have stool-softening effect

a-Glucosidase inhibitors

Insulin and insulin analogs

Promotes weight loss and reduces blood fat
and cholesterol levels
Does not cause hypoglycemia when taken alone

Facilitates weight loss
Lowers blood glucose levels
Improve lipid profile

COMPARISON

Biguanide

All type 1 and
some type 2

Type 2 when nonpharmacologic
therapy no longer
controls blood
glucose levels

Oral drug therapy

Sulfonylureas

Type 1 in
combination with
insulin therapy
and type 2

Indications

Nonpharmacologic
management, including
diet and exercise

Interventions

TABLE 3.

May cause hypoglycemia

Hypoglycemia can occur when
taken with insulin or insulin
analogs
May reduce effectiveness of
oral contraceptives

May cause diarrhea

May contribute to hypoglycemia
May cause weight gain
Potential for lactic acidosis

Major side effects
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have not responded to treatment; new medications are currently in development for this
therapy resistant population, and continued research efforts are warranted.
A disease with a complex etiology
Identifying and managing diabetes is complex because of its dual nature (type 1 vs. type
2) and its multifactorial origins. Genetic and environmental factors are believed to play a significant role in both types of diabetes. Type 1
diabetes usually begins in childhood and is
caused by an abnormal autoimmune process
that destroys cells in the pancreas, which
makes insulin.23 This accounts for the total absence of insulin, the hallmark of type 1 diabetes, which requires daily insulin therapy to
sustain the patient. While environmental factors, such as diet and exercise, can affect the
management of type 1 diabetes, they do not
cause the disease.
In type 2 diabetes, genetic and environmental causes are difficult to untangle. Studies have
indicated that the condition aggregates in families, especially those with a preponderance of
obese and/or sedentary family members. 6 It remains unverified whether this link is genetically or environmentally determined, but in all
likelihood familial type 2 diabetes probably
stems from both factors. In addition, children
of women who develop diabetes during pregnancy have a greater chance of developing it
themselves compared to those whose mothers
develop diabetes after pregnancy. This suggests prenatal involvement.6
One theory, the “thrifty genotype hypothesis,” suggests that nutritional deprivation during fetal development increases the likelihood of
type 2 diabetes. Some infants may have a specific genetic makeup that allows them to survive
despite low levels of prenatal nutrition, but this
same genotype increases their risk of developing diabetes. Metabolism and insulin resistance
may also be genetically linked to diabetes, but
according to diabetes researcher Peter Bennett,
“genetic determinants have been difficult to elucidate because there are multiple biochemical
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and metabolic abnormalities, probably polygenic, and the situation is complicated by environmental factors and late age of onset.”6
In addition, physiologic changes that occur
with age factor into the diabetes equation, both
in terms of onset and treatment. Changes such
as alterations in metabolism and body composition affect glucose tolerance in almost everyone. As people age, some impairment in glucose
blood levels occurs, with average increases of 5
to 10 mg/dL per decade after age 50.39 But for
more than half the population over age 65, these
age-related physiologic changes, coupled with
other factors such as nutrition and activity level,
lead to clinically diagnosable type 2 diabetes.39
Diabetes in special populations
All the factors implicit in the origins of diabetes—family genetics, environment and behavior, and the physiology of aging and comorbidity—contribute to subpopulations at
special risk for developing the disease. Diabetes may also manifest or progress differently
in these high-risk groups. Likewise, the management of diabetes in subpopulations can be
varied to meet the diversity of group and individual healthcare needs. This section takes a
closer look at several groups for whom diabetes
prevention and individualized treatment is essential to ensuring positive health outcomes.
Diabetes in women. Diabetes affects more than
8% of all women in the United States, a percentage that is similar to that in the male population. But although men and women are at
equal risk for developing diabetes, the repercussions of the disease can be particularly dangerous for women. For example, women with
diabetes have an increased risk of complications
during pregnancy. Also, women have a much
greater chance (up to 50% higher) than their
male counterparts of developing diabetic ketoacidosis, which poses a serious health threat.40
Compared to women without diabetes,
women with diabetes are nearly eight times
more likely to suffer from peripheral vascular
disease (PVD) in which blood and oxygen flow
to the lower extremities is reduced. PVD causes
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intermittent claudication (leg pain during exercise), and this condition predisposes the sufferer to a 3 to 4 times greater risk of several cardiovascular diseases.13,40
Women with diabetes who are also pregnant
face the possibility of additional complications.
Because the body demands more insulin during
pregnancy, extremely strict blood glucose control is essential for women who are pregnant or
trying to conceive. The early infant mortality rate
for babies born to mothers with diabetes is as
much as two to three times higher compared to
children of women who do not have diabetes.
Moreover, this risk increases when preconception care of the mother is inadequate or absent.
Pregnant women with diabetes are at increased
risk of having high birthweight newborns, thus
increasing the need for cesarean section to three
to four times that of the general population. Dangers also include greater risks of toxemia and hydramnios (excessive accumulation of the amniotic fluid). Both are serious health concerns for
the mother and child.40
Even women who do not have diabetes when
they conceive are still at risk for an alternate
form of the condition known as gestational diabetes. Gestational diabetes develops in 2% to
5% of all expectant women without diabetes
but resolves after pregnancy. However, gestational diabetes increases the chances of complications during pregnancy and increases the
chances of both child and mother developing
type 2 diabetes postdelivery.41
Diabetes in children and adolescents. Diabetes is
the most common severe chronic disease of
childhood. The majority of children and adolescents with diabetes are diagnosed with type 1
disease. Type 1 diabetes in children usually occurs during puberty, and the disease runs in families, suggesting a genetic component. Unlike
type 2 diabetes, the incidence of type 1 diabetes
is greater in whites than in other racial groups.
The number of youths with type 2 diabetes
is growing. Children with type 2 diabetes tend
to be overweight and slightly older at diagnosis, compared to youths with type 1 diabetes.
They may have a family history of type 2 dia-
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betes and are also likely to be African American, Native American, or Latino.
Treatment of children with diabetes requires
special consideration. Studies suggest that
achieving and maintaining an optimal blood
glucose level is especially important in this age
group. The Pittsburgh Epidemiology of Diabetes Complications Study revealed a relationship between glycemic control and disease
complications in childhood onset diabetes.41 In
cases where there was very poor gylcemic control, retinal complications have occurred before
puberty. While the evidence is conflicting, the
number of years a child lives with diabetes before puberty may correlate with an increased
risk for future vascular complications.42
The nature of childhood itself uniquely affects diabetes and its management. Special considerations must be taken into account for this
population. Intense activity during play or
sports, high sugar and fat content of snack
foods marketed toward children, and the general level of personal responsibility for self-care
all significantly impact blood glucose levels
and diabetes management in children. One key
to successful treatment is consistent blood glucose monitoring followed by therapeutic and
behavioral adjustments to reach optimal levels.42 Depending on age, children may or may
not be old enough or responsible enough to understand and adhere to a program of monitoring and management. Adherence among children can be increased by intensive diabetes
education for the patient and his or her family.
For children taking insulin who require more
flexibility in daily activity and dietary habits,
four injections per day, compared to two, may
result in better glycemic control.42
For all of these reasons, childhood diabetes
requires early detection and individualized
treatment to optimize outcomes at onset and
throughout later life. More research is required
to determine the special characteristics unique
to children with diabetes to maximize the success of current therapies or suggest innovations
that could improve diabetes care for children.
Whatever therapy is selected, tight glycemic
control is essential for good outcomes.
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Diabetes in the elderly. The elderly are discussed in the diabetes medical literature more
than any other patient population identified in
this paper. Perhaps the abundance of literature
reflects the significant impact diabetes has on
seniors: half of all people with diabetes are
older than 55 years of age.40 Because aging is
an independent risk factor for type 2 diabetes,
everyone has a vested interest in understanding diabetes prevention, risk factors, and early
detection. For those people who do acquire diabetes during their adult or later adult lives,
understanding diabetes management options
is critical as well.
What are the special considerations for older
patients with diabetes? Primarily, the complications of diabetes are more prevalent and
more dangerous for older individuals. Because
aging reduces the body’s physiologic reserves,
alters its metabolism, and diminishes organ
function, diabetes complications are more common in this age group. For example, the prevalence of diabetic heart disease increases with
age. Likewise, kidney infections are twice as
common in the 65-plus diabetic population as
in the population without diabetes.40 In addition to complications caused by diabetes, the
increased prevalence of comorbidities in older
patients is a special concern for people with diabetes. Comorbidity, or the coexistence of two
or more diseases, occurs more often with age,
and its presence increases morbidity, mortality,
and medical resource use.43 The specific concerns associated with diabetes with comorbidity are discussed later in this paper.
One specific concern about diabetes in the elderly is their increased risk of hypoglycemia.
Because the risk of hypoglycemic episodes is
greater in the aged, monitoring blood glucose
levels carefully is essential, especially when hypoglycemic medications are used. First-line
treatment should include diet and exercise
modifications, if possible. Then, if pharmacotherapy is required to control blood glucose
levels, selection should be based on the patient’s individual needs.
However, some diabetes medications should
generally be avoided in the elderly. For example,
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chlorpropamide, an oral sulfonylurea, has a long
half-life and high incidence of hypoglycemia and
is not preferable for most older patients.9 A better option in this class of drugs are shorter-acting, less hypoglycemic agents such as glipizide.
When initiating drug therapy, elderly who may
have altered metabolism should begin with half
the recommended dosage given to younger patients and titrate to a therapeutic level. Also, patients with renal or hepatic insufficiency should
not be treated with sulfonylureas.
Diabetes in certain racial and ethic groups: Hispanic Americans, Native Americans, African Americans face greater risks. Similar to the elderly, certain ethnic and racial groups face greater risks
of type 2 diabetes and its complications. The
comparative prevalence of type 2 diabetes in
these groups is astounding: 24% of all Mexican
Americans, 26% of all Puerto Ricans, 11% of
African Americans, 12% of Native Americans,
and 16% of Cuban Americans have diabetes
compared to 6% in the general population.
Asian Americans and Pacific Islanders appear
to be at greater risk also, although prevalence
data are limited.2 In one specific tribe of Native
Americans residing in Arizona, the prevalence
of type 2 diabetes is higher than in any other
group worldwide, with 50% of adults ages 30
to 64 having the disease. Among Native Americans overall, complications from diabetes are
the most frequent cause of death from disease.
Several factors account for higher rates of diabetes morbidity and mortality in ethnic
groups. Environmental factors may include access to quality, affordable healthcare, varying
levels of functional health literacy, effective patient education, diet, exercise, and other health
behaviors including alcohol and tobacco use.
Although these socioeconomic and behavioral
factors play a considerable role, recent research
concludes that ethnicity alone is strongly associated with diabetes and its control in some minorities.44 This finding implicates genetic variables as risk factors for type 2 diabetes; if so,
recent and ongoing research in genomics and
biotechnology could offer improved care options for subpopulations with a predisposition
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to the disease. At any rate, the conclusions suggest that continued efforts to support biotechnological innovation are warranted to promote
equitable diabetes care for minority groups.
Diabetes and comorbidity
Comorbid conditions are common in patients with diabetes. In many cases, diabetic
complications account for these conditions; in
others, the coexisting condition(s) precedes or
occurs independent of diabetes. In either situation, comorbidity requires specialized care
regimens to optimize clinical outcomes. Comorbidity often generates disease synergies
more debilitating than the additive effects of
each individual disease. Common comorbidities in patients with diabetes include obesity,
cardiovascular diseases, depression, and nerve,
eye, and kidney diseases. While a discussion of
all diseases that commonly coexist with diabetes is too broad for the scope of this paper,
the following sections focus on two major comorbid illnesses associated with diabetes: cardiovascular conditions and depression.
Diabetes and cardiovascular conditions. Researchers have extensively studied the connection between diabetes and cardiovascular disease (CVD). In the United States, cardiovascular
disease is the leading cause of death in both men
and women with diabetes. The mortality rate
associated with CVD is significantly higher in
women than in men and increases with advancing age in both men and women.13
When treating patients with comorbid diabetes and CVD, minimizing the deleterious effects of both conditions is essential. If the treatment of one disease is emphasized over the
other, the undertreated disease can exacerbate
the seemingly well-managed one. However, intensive risk factor modification improves the
prognosis of patients with comorbid diabetes
and CVD.45 Many risk factors, such as poorly
controlled blood glucose levels, hypertension,
and dyslipidemia, can be minimized with drug
therapy.
The Multiple Risk Factor Intervention Trial
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(MRFIT), a 12-year analysis of coronary heart
disease (CHD), revealed higher mortality rates
for patients with diabetes. Hypertension, hypercholesterolemia, and cigarette use further increased these rates in individuals with diabetes. 45 Controlling these risk factors with
pharmacotherapy can reduce the risk of cardiovascular events. Strict control of blood pressure and blood glucose levels appears to be a
primary therapeutic goal.13 Blood pressure can
be reduced by using various classes of antihypertensive agents such as diuretics, angiotensin-converting enzyme (ACE) inhibitors, bblockers, and calcium channel blockers. Within
each drug class, there are numerous agents
from which to choose. The specific choice of an
antihypertensive agent is important in that, first
and foremost, it must reduce blood pressure,
and second, it should be selected to meet specific patient needs, taking into consideration
age, comorbidities, and other health factors.
Antihypertensives agents that increase blood
glucose levels (e.g., diuretics) should be
avoided in patients with diabetes. Recently, aspirin therapy has also been recommended by
the American Diabetes Association as a consideration for adults with diabetes who have CVD
or CVD risk factors. While nearly every diabetic
adult in the United States has at least one risk
factor for CVD, only 20% take aspirin regularly,46 suggesting that undertreatment may
play a large role in inadequately controlled risk
factors for comorbid diabetes and CVD.
Diabetes and depression. Although not usually
indicated as a complication of diabetes in the
same way as heart disease and obesity, depression is a common comorbid condition facing
many patients. A recent study by Anderson and
colleagues47 concludes that having diabetes
doubles the odds of comorbid depression. This
National Institutes of Health (NIH)-sponsored
meta-analysis of 42 diabetes/depression studies showed that major depression was present
in 14.7% and elevated depression symptoms in
26% of diabetic patients.47
Now that the medical community generally
acknowledges that mental status can impact the
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course of comorbid physical illnesses,11 these
rates of depression are a serious consideration in
terms of treating people with diabetes. However,
studies have suggested that even in the general
population, depression is undertreated.48
Inadequate treatment of depression in patients with diabetes further compromises health
status for several reasons. First, a depressed patient may not be motivated to follow the rigid
self-care routines required to maintain good
blood glucose control. Second, depression often
results in appetite and weight fluctuations that
can impact diabetes progression or encourage
undesirable and dangerous hypoglycemic or
hyperglycemic events. In addition, diabetes can
negatively impact major depression by increasing the frequency of recurrent depressive
episodes in the five years following diagnosis.11
Diabetes increases the risk of subclinical depressive symptoms as well.47
Recent reports reveal that treating comorbid
depression in patients with diabetes can improve glycemic control without interfering with
diabetes medications. Both tricyclic antidepressants and selective serotonin reuptake inhibitors
(SSRI) have shown efficacy in treating depression.49 However, SSRIs offer fewer side effects
and a lower risk of a direct hyperglycemic effect.11,50 A more recent study of patients with diabetes with depression showed that after only 8
weeks of treatment with the SSRI fluoxetine, depressive symptoms decreased, and glycemic
control showed improvement. 51

PROMOTING QUALITY, COSTEFFECTIVE DIABETES MANAGEMENT
THROUGH INDIVIDUALIZED CARE
With the efficacy of intensive, individualized
diabetes treatment established, the medical research community is now focused on how to
achieve this outcome in a cost-effective manner. The primary cost of treating diabetes
comes from short-term hyperglycemia and
long-term complications.52 One analysis of intensive treatment of type 2 diabetes found that
achieving normal blood sugar levels would re-
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duce the incidence of blindness by 72% and
end-stage renal disease by 87%, lower extremity amputation by 67%, and raise life expectancy by 1.4 years.53 Importantly, these facts
and figures imply that good clinical and economic outcomes are aligned. By reducing the
incidence of diabetes complications, costs
would decrease as well.
Improved clinical practice in diabetes management is one step toward quality, cost-effective outcomes. In July 1995, the American Diabetes Association convened a panel of experts
to develop a consensus statement on the pharmacologic treatment of hyperglycemia in type
2 diabetes. The panel, relying on evidence from
the DCCT, recommended that if progress toward glycemic goals was not apparent within
a 3-month period after initiation of diet and exercise, then use of a pharmacologic agent is appropriate. 26 Before the availability of antidiabetic drugs, approximately 35% of type 2
patients were treated with insulin alone. While
clinically effective for glycemic control, insulin
therapy requires diligent compliance on the
part of the patient. For some individuals—especially children, the elderly, and patients with
low functional health literacy—complying
with a rigid drug regimen is a considerable
task. Thus, achieving this compliance presents
the clinician with the challenge of educating the
patient about self-administration and dose adjustment.54 Moreover, compliance is linked to
factors such as side effects, ease of administration, affordability of medication, and the patient’s perception of effectiveness. Therefore,
selecting the specific combination of medications that will meet an individual patient’s
needs is essential to encouraging compliance
and improving outcomes.
Fortunately, the array of independently acting antidiabetic medications available makes
possible a number of combination therapies,
and recent research focusing on the efficacy of
particular combinations has revealed opportunities where judicious selection among antidiabetic agents of similar efficacy may have beneficial effects on complications of diabetes or
comorbid conditions.
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The availability of antidiabetics agents with
complementary mechanisms of actions allows
clinicians to select treatments that have additive benefits and avoid detrimental side effects.
A meta-analysis of nine randomized controlled trials published since 1957 was conducted in 1999 to compare the efficacy of
biguanides and sulfonylureas. Although the efficacy is similar for biguanides and sulfonylureas, sulfonylurea treatment was associated
with an increase in body weight, and biguanides
with a decrease, suggesting that a biguanide
may be preferred for obese patients.55

DIABETES PUBLIC POLICY
IMPLICATIONS
Healthy People 2010, the nation’s comprehensive plan for improving public health, includes
goals for reducing the burden of diabetes and
improving the quality of life for all persons who
have or are at risk for the disease. Specifically, it
states a goal of reducing by 10% the number of
deaths from CVD in persons with diabetes. Over
the past ten years, diabetes has been a leading
cause of death in the United States, primarily due
to diabetes-related CVD. Achieving reductions
in addressable risk factors, such as uncontrolled
hypertension, smoking, and high cholesterol,
could significantly reduce the incidence of CVD
in persons with diabetes.
Related goals in Healthy People 2010 are directed toward reducing the incidence of other
costly, life-shortening complications among
patients with diabetes, including end-stage renal disease, blindness, lower extremity amputation, and complications of pregnancy. Because weight reduction ameliorates metabolic
abnormalities characteristic of diabetes and
may help prevent complications of the disease,
addressing overweight and obesity is of major
importance in reaching this goal.
To reach the Healthy People 2010 goals, there
must be improvements in the practice of
healthcare for people with diabetes. Measurement and monitoring of glycosylated hemoglobin (HbA1c) levels is the gold standard for
glycemic control as specified in guidelines, yet

it is still underused, especially in primary
care.56 There is considerable interest in the effect of managed care on diabetes treatment
patterns. Interest has grown with the spread
of managed care coverage to higher-risk
Medicare beneficiaries in the late 1990s. Referral to out-of-network physicians and specialists is a more complex process in managed
care; therefore, diabetics are relying increasingly on care and education from their primary care physicians.
The long-term impact of managed care on diabetes treatment patterns is still not known;
however, some believe increased use of oral antidiabetic agents may be attributed in part to
managed care practices. Moreover, with the introduction of diabetes treatment-related performance measures into the National Committee for Quality Assurance, Health Plan
Employer Data and Information Set (HEDIS®),
many managed care plans have developed
comprehensive diabetes treatment programs to
promote early detection of diabetes and related
conditions through educational programs and
screenings. While front-end financial investments such as increased drug spending and diabetes disease management are costly, the potential return-on-investment could be doubly
advantageous. By improving clinical outcomes
through better diabetes prevention and management, overall expenditures, especially those
associated with long-term complications, could
be significantly reduced.

DIABETES: a tool for a complex condition
Creating cost-effective diabetes management
plans to meet the individual needs of a diverse
patient population is dependent on many factors. When one or more of these factors are overlooked, therapy plans may be less than optimal,
clinical outcomes less positive than expected,
and financial returns inconsequential. A complex condition such as diabetes requires a comprehensive strategy to address clinical and economic outcomes adequately. To help ensure that
all factors are considered, we have designed a
mnemonic tool to remind patients, providers,
and policy-makers of the many facets of indi-
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vidualized diabetes care. Our DIABETES device
addresses what we believe to be the essential
components of individualizing pharmaceutical
therapy in the treatment of diabetes.

Delivery:

Matching a dose delivery method
with a patient and his or her special needs is a
key step toward ensuring compliance and encouraging good glycemic control. Patients who
are comfortable with their insulin delivery system will be more willing and better able to adhere to their diabetes plans.

Integration

of Care: When all care providers
and sites are well integrated, the opportunity
to maximize the quality of diabetes care is at
its peak. Integrated care includes communication among physicians, specialists, pharmacists, nurses, and other people involved in the
patient’s care process. It also means that systems and programs have been implemented to
easily facilitate such communication. For example, information-sharing systems supported
by Web-based and electronic tools can connect
all of a patient’s care providers, and in some
cases even the patient, to form a network of integrated care for each individual. Also, integrated disease management (DM) programs
that address multiple therapeutic areas, such as
the combined diabetes and heart disease DM
programs that have recently evolved, are creating care processes that address the complexity of diabetes and comorbid disease.

Adherence: Adherence may be more important
in diabetes than in any other disease state. Adherence promotes strict glycemic control, and
glycemic control is the best method for controlling diabetes and preventing its complications. That is why promoting adherence is vital
to diabetes care. Adherence can be encouraged
through offering intensive diabetes education,
creating convenient dosing regimens to fit individual lifestyles, addressing the emotional
and psychological needs of patients with diabetes, minimizing medication side effects, providing following-up care through PCP, nurse
practitioners or structured DM programs, and
designing accessible and affordable diabetes
management plans for individual patients.
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Behavior Change: To

promote individualized
care for people with diabetes, behavior change
will need to occur at the patient, provider, and
policy level. We know this because although effective diabetes diagnostics, therapies and treatment guidelines exist, there are still nearly 5 million cases of undiagnosed diabetes in America.
Of the patients who are diagnosed, many still
suffer uncontrolled blood glucose levels that can
lead to costly clinical complications. The tools to
prevent and manage diabetes are out there, and
new and improved tools are developed every
day. But the systems, processes, and individual
behaviors of all diabetes stakeholders must maximize the use of these tools if the fight against
diabetes is to succeed. Behavior change can be
affected through education, incentives, policies,
and regulations. All of these methods must be
explored to enhance diabetes outcomes.

Education: Education that occurs at every contact point between the patient and care
providers is needed. Providers who take advantage of every “teachable moment” will be
most successful in helping their patients develop the skills and attitudes that they need to
manage their diabetes. Opportunities for educating patients may be less formal, such as impromptu discussions during office or pharmacy visits, or more structured, such as
planned patient education meetings offered as
part of a larger diabetes DM program. Education can be provided in many modalities—patient literature, videos, one-on-one, or group
instruction. Studies have shown clearly that a
patient’s functional health literacy is directly
connected to the kind of care he or she seeks
and receives and to health outcomes. Therefore, maximum effort is needed to provide diabetes education that reaches all patients.

Treatment Options: Each year, the

American
Diabetes Association, with the support of expert clinicians and researchers, reviews and revises treatment guidelines and recommendations for caring for people with diabetes. These
guidelines, along with the myriad of pharmacologic and nonpharmacologic treatment option for diabetes, provide the foundation for
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quality diabetes care. Yet the existence of
guidelines and treatment options is not
enough. The wide range of diabetes medications must be made available for all patients if
individualized care is to be achieved.

Economics: Healthcare coverage, be it private
or publicly funded, that limits access to the full
span of diabetes medications could compromise health outcomes for patients. Moreover,
we know that compromised health outcomes
in diabetes lead to extraordinarily expensive
complications. The front-end costs associated
with quality preventive diabetes care and management are an investment that has the potential to alleviate at least a portion of the financial burden associated with the high costs of
uncontrolled diabetes. Controlling diabetes
may be expensive, but is it as expensive as allowing the disease to run rampant through our
national and personal healthcare resources?

Special

Circumstances: For pharmaceutical
care to be truly individualized, any special circumstances regarding the patient need to be
considered when developing a treatment plan.
Although this is to some degree true for any
disease or medical condition, it is especially relevant in the case of diabetes because of its pervasiveness. Diabetes infiltrates all aspects of an
individual’s life, from what to choose for breakfast to how to schedule daily activities around
administering medications and monitoring
blood glucose levels. Therefore, any situations
that are unique to an individual patient have
the potential to impact the diabetes care plan.
Examples of such factors include socioeconomic issues like living environment, transportation, and financial resources as well as
clinical issues such as comorbidities and general health status. At least one individual on
the patient’s diabetes care team needs to be prepared to discuss any issue that might impact
the diabetes treatment plan.
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